AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Share News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 255.50
Bid: 254.00
Ask: 257.00
Change: 14.30 (5.93%)
Spread: 3.00 (1.18%)
Open: 245.00
High: 259.50
Low: 240.00
Yest. Close: 241.20
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Avacta Collaborates With Liverpool School For Covid-19 Test Validation

Fri, 7th Aug 2020 09:53

(Alliance News) - Avacta Group PLC said Friday it has partnered with the Liverpool School of Tropical Medicine for the clinical validation of the rapid, saliva-based coronavirus antigen test which is being developed with life sciences firm Cytiva.

Shares in the Wetherby, England-based developer of Affimer biotherapeutics and reagents were up 5.2% at 141.00 pence on Friday in London.

Cytiva was formerly part of General Electric Co, when it was known as GE Healthcare Life Sciences.

The Liverpool School of Tropical Medicine is dedicated to researching tropical medicine and disabling diseases, and has a research portfolio of GBP320 million.

Under the collaboration, LSTM will carry out a clinical validation of the SARS-CoV-2 rapid antigen test in its laboratories on patient samples, gathered from the UK, Africa and South America.

Clinical validation is the process of evaluating the performance of a diagnostic test using real patient samples. Such a process generates the sensitivity and specificity performance parameters which are most often used to define the performance of a diagnostics test.

"I am delighted to have established this collaboration with the Liverpool School of Tropical Medicine. It is an important partnership which provides Avacta with access to patient samples both in the UK and abroad, where the incidence of the disease is currently much higher, to ensure prompt access to a sufficient number of samples for clinical validation," said Chief Executive Alastair Smith.

Due to the high prevalence of the diseases in the latter two regions, samples for prospective studies have become more readily available, and could speed up the validation process.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

22 Apr 21 12:17

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

20 Apr 21 15:18

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

20 Apr 21 12:17

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

20 Apr 21 11:35

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

15 Apr 21 14:56

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

6 Apr 21 13:53

Avacta signs global distribution deal with Abcam

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.

6 Apr 21 11:03

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

25 Mar 21 15:57

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

9 Mar 21 20:19

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

9 Mar 21 11:08

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

8 Mar 21 19:07

Avacta confirms efficacy of test on variant Covid-19 strains

(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.

8 Mar 21 11:06

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

24 Feb 21 11:45

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

24 Feb 21 10:25

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

22 Feb 21 11:01

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.